ArticleCell biochemistry and biophysics2026
Optimization of Non-Cross-Linked Hyaluronic Acid and Adipose-Derived Mesenchymal Stem Cells for Regenerative Applications: an in Vitro Study.
Article in Cell biochemistry and biophysics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hyaluronic acid (HA) and adipose-derived mesenchymal stem cells (AD-MSCs) are both promising agents for skin rejuvenation. Combining non-cross-linked HA with AD-MSCs may enhance regenerative outcomes; however, the optimal HA concentration and its compatibility with AD-MSCs remain unclear. This study evaluated AD-MSCs encapsulated in varying concentrations of non-cross-linked HA, including a Proage® HA formulation, to identify the most biocompatible scaffold for regenerative applications. AD-MSCs were isolated from human adipose tissue and characterized using flow cytometry and tri-lineage differentiation. Cells were encapsulated in HA matrices ranging from 2% to 10%, including a Proage® 2% HA formulation. Metabolic activity was assessed using the Alamar Blue assay on Days 1, 3, 5, and 7. Gene expression of COL1A1, COL3A1, LMNA, IL10, TIMP1, MMP1, CD49f, and CD146 was analyzed via qRT-PCR to evaluate extracellular matrix remodeling and inflammatory responses. AD-MSCs maintained high metabolic activity across HA concentrations, with 4% HA demonstrating the highest metabolic activity by Day 5, whereas higher concentrations (>5%) reduced activity. Gene expression analysis showed significant upregulation of COL1A1, COL3A1, LMNA, TIMP1, CD49f, and CD146 in 3D HA conditions compared with 2D culture. Specifically, 4% HA increased COL1A1, LMNA, CD146, and TIMP1 expression, while the Proage® HA formulation significantly upregulated COL3A1, LMNA, CD49f, CD146, and TIMP1. No significant changes were observed for IL1B or MMP1, and IL10 showed a non-significant upward trend under 3D conditions. Overall, non-cross-linked 4% HA provided an optimal microenvironment for AD-MSC metabolic activity and regenerative gene expression. The Proage® 2% HA formulation also demonstrated strong biocompatibility and regenerative potential, particularly through upregulation of collagen and stemness markers. These findings indicate that AD-MSCs tolerate the 4% non-cross-linked HA scaffold well, maintaining high metabolic activity and growth potential, thereby supporting its potential use to enhance regenerative outcomes in skin rejuvenation therapies.
Indexed as
Identifiers
41854982What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.